Healthcare

PainChek Ltd (ASX:PCK) has appointed experienced US medical technology executive Karen Holzberger as Chief Executive Officer, effective 17 August 2026. The appointment follows an international recruitment process and comes as the company advances its United States commercial strategy after receiving FDA De Novo clearance …

INOVIQ (ASX: IIQ) has positioned itself within two rapidly developing areas of healthcare innovation: liquid biopsy cancer diagnostics and exosome-based therapeutics.

Mayne Pharma Group (ASX:MYX) returned to investor focus after announcing a new chief financial officer as the specialty pharmaceutical company continues executing its strategy centred on women's health and dermatology products.

Neurizon Therapeutics Limited (ASX:NUZ) has announced a significant clinical development milestone after completing enrolment for Regimen I of the Phase 2/3 HEALEY ALS Platform Trial evaluating its lead investigational therapy, NUZ-001. The company also brought forward the expected timing of topline efficacy and safety …

Key Highlights4DMedical (ASX: 4DX) fell 14.38% to A$3.245 on 17 July 2026 (confirmed; −A$0.544).Shares resumed trading on 17 July after a 16 July halt tied to an announcement about the proposed AIRCARE for Vets Act (H.R. 9666), which would authorise up to US$20 million …

Paradigm Biopharmaceuticals (ASX: PAR) has returned to investors' watchlists as attention builds around its late-stage clinical programme for knee osteoarthritis. While no single company announcement explains the recent market interest, anticipation surrounding the upcoming interim Phase 3 trial analysis has kept the biotechnology company …

Australian Clinical Labs (ASX: ACL) has remained in focus following recent financial updates that highlighted improving underlying earnings, continued capital management and operational efficiency initiatives.